Metastatic prostate cancer market to grow strongly through 2036 with new targeted therapies emerging.

The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in major markets like the US and EU, is expected to expand significantly due to rising prostate cancer cases, improved diagnostics, and a robust pipeline of innovative drugs from leading pharma companies. Upcoming therapies such as 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and Mevrometostat are poised to reshape treatment standards and drive market growth through 2036.